

**FORM 6-K**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934  
for the month of April 2007

Compugen Ltd.  
(Translation of registrant's name in English)

72 Pinchas Rosen Street, Tel-Aviv 69512, Israel  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover  
Form 20-F or Form 40-F.

Form 20-F X      Form 40-F \_\_\_\_

On April 26, 2007 Compugen Ltd. (the "Registrant") issued a Press Release, filed as  
Exhibit 1 to this Report on Form 6-K, which is hereby incorporated by reference herein.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has  
duly caused this report to be signed on its behalf by the undersigned, thereunto duly  
authorized.

Compugen Ltd.  
(Registrant)  
By: /s/ Nurit Benjamini  
Title: Chief Financial Officer  
Date: April 26, 2007

**Exhibit 1**



**Compugen Ltd. to Review First Quarter 2007 Results on**

**Tuesday, May 1, 2007**

*Conference call to be held at 10:00 AM EST*

**TEL AVIV, ISRAEL, April 26, 2007** - Compugen Ltd. (NASDAQ: CGEN) today announced that the Company plans to host a live conference call and webcast at 10:00 AM EST on Tuesday, May 1, 2007 to review first quarter 2007 results. The quarterly results will be released prior to the conference call.

To access the conference call, please dial 1-888-281-1167 from the US or +972-3-918-0610 internationally. The call will also be available via live webcast through Compugen's Website, located at [www.cgen.com](http://www.cgen.com).

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-782-4291 from the US or +972-3-925-5901. The replay will be available until 12 noon EST on May 3, 2007.

**About Compugen**

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company's powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company's decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen's product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases. The Company's primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen's corporate Website at [www.cgen.com](http://www.cgen.com).

***Company contact:***

Nurit Benjamini  
Chief Financial Officer  
Compugen Ltd.  
Email: [nurit@cgen.com](mailto:nurit@cgen.com)  
Tel: +972-3-7658-525